MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Revenue 2011-2026 | BMY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.2 B | 48.3 B | 45 B | 46.2 B | 46.4 B | 42.5 B | 26.1 B | 22.6 B | 20.8 B | 19.4 B | 16.6 B | 15.9 B | 16.4 B | 17.6 B | 21.2 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 48.3 B | 15.9 B | 30.2 B |
Quarterly Revenue Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.3 B | 11.2 B | 11.9 B | 12.2 B | 11.9 B | 11 B | 11.2 B | 11.3 B | - | 11.2 B | 11.9 B | 11.6 B | - | 11.6 B | 11.7 B | 11.1 B | 11.1 B | 10.5 B | 10.1 B | 10.8 B | 7.94 B | 6.01 B | 6.27 B | 5.92 B | 5.97 B | 5.69 B | 5.7 B | 5.19 B | 5.45 B | 5.25 B | 5.14 B | 4.93 B | 5.24 B | 4.92 B | 4.87 B | 4.39 B | 4.29 B | 4.07 B | 4.16 B | 4.04 B | 4.26 B | 3.92 B | 3.89 B | 3.81 B | 4.44 B | 4.06 B | 4.05 B | 3.83 B | 4.19 B | 3.74 B | 4.44 B | 5.25 B | 5.45 B | 5.34 B | 5.43 B | 5.01 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.3 B | 3.74 B | 7.06 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
21 M | $ 2.08 | -14.4 % | $ 214 M |  USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Altimmune
ALT
|
20 K | $ 4.2 | -2.67 % | $ 298 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aptevo Therapeutics
APVO
|
3.11 M | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Aquestive Therapeutics
AQST
|
57.6 M | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
152 M | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
407 M | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
argenx SE
ARGX
|
36.4 M | $ 756.71 | -1.33 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
823 K | $ 10.91 | 1.58 % | $ 394 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arvinas
ARVN
|
263 M | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 231.56 | -0.83 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.39 | -1.63 % | $ 8.16 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
81 K | $ 1.17 | -0.85 % | $ 35.2 M | USA |
 |
Atossa Therapeutics
ATOS
|
1.76 K | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
129 M | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
77.1 M | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.68 | -1.75 % | $ 429 M | Britain |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Atea Pharmaceuticals
AVIR
|
351 M | $ 4.69 | 0.21 % | $ 395 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
2.08 B | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |